STOCK TITAN

Enlivex Therapeutics Ltd - ENLV STOCK NEWS

Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.

Enlivex Therapeutics Ltd (ENLV) is a clinical-stage biopharmaceutical company pioneering macrophage-reprogramming therapies through its lead candidate Allocetra. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic developments across its pipeline targeting immune dysregulation.

Access primary-source ENLV news including clinical trial results, research collaborations, and regulatory filings related to Allocetra's development in sepsis, osteoarthritis, and autoimmune conditions. Our curated news collection enables efficient tracking of the company's progress in creating off-the-shelf cell therapies designed to restore immune homeostasis.

Key updates include advancements in Phase I/II trials, manufacturing partnerships, and peer-reviewed data publications. Bookmark this page for direct access to ENLV's official press releases and objective third-party analysis of their innovative approach to immune rebalancing therapies.

Rhea-AI Summary
Enlivex Therapeutics (ENLV) announces positive results from Phase II study of Allocetra™ in sepsis patients, showing significant reductions in SOFA scores and mortality rates. The study indicates a potential market opportunity for Allocetra™ in high-risk sepsis patients originating from urinary tract infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.02%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics and Unusual Machines Inc. will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Enlivex Therapeutics, led by CEO Oren Hershkovitz, offers a promising investment opportunity in the biopharmaceutical sector with its innovative Allocetra™ cell therapy platform. The technology aims to reset immune cells for treating inflammatory and autoimmune diseases. On the other hand, Unusual Machines, under CEO Allan Evans, is focusing on the drone industry, acquiring valuable IP and brands to cater to various sectors. The company's subsidiaries, Fat Shark and Rotor Riot, are leading in FPV products and services, positioning Unusual Machines for long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) launches a new trial for AllocetraTM, a cell therapy to treat osteoarthritis in the knee. The therapy aims to reprogram macrophages and rebalance the immune microenvironment. The trial, authorized by the Israeli Ministry of Health, will evaluate efficacy, safety, and tolerability in up to 160 patients. This innovative approach could provide a new option for patients suffering from knee osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) is developing AllocetraTM, a cell therapy for sepsis treatment. The phase 2 trial of AllocetraTM has enrolled all 120 patients and is expected to release data by Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (ENLV) has received a new patent, US 11,883,429, from the U.S. Patent and Trademark Office for its immunotherapy product candidate, AllocetraTM. The patent provides additional intellectual property protection for the product's composition and manufacturing method in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
none
-
Rhea-AI Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the authorization from the Israeli Ministry of Health for a multi-country Phase I/II trial to evaluate the efficacy, safety, and tolerability of Allocetra™ injections into the target knee joint of up to 160 moderately to severely symptomatic osteoarthritis patients. The trial will consist of a safety run-in, open-label dose escalation phase, followed by a double-blind, randomized, placebo-controlled stage. The primary measurements will assess joint-pain and joint-function compared to placebo at three months, six months, and 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
Rhea-AI Summary
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) completes enrollment in Phase II trial for Allocetra™ in patients with sepsis. Topline data expected in late Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.96%
Tags
-
Rhea-AI Summary
Enlivex focuses on inflammatory and autoimmune indications, initiates clinical program in osteoarthritis, and plans to seek external collaborations for oncology assets. Workforce reduction of approximately 50% expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.73%
Tags
-
Rhea-AI Summary
Enlivex Therapeutics to present corporate update at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
conferences
Enlivex Therapeutics Ltd

Nasdaq:ENLV

ENLV Rankings

ENLV Stock Data

20.34M
19.34M
5.59%
22.15%
0.52%
Biotechnology
Healthcare
Link
Israel
Ness Ziona